DelveInsight's Parkinson's disease Psychosis market Report provides comprehensive insights into the epidemiology and market dynamics across the 7MM. LAS VEGAS , NV, UNITED STATES, January 30, 2025 ...

Hallucinations and delusions in Parkinson's disease are known as Parkinson's disease psychosis. Learn more about Parkinson’s ...

Psychosis is a common symptom of Parkinson's disease. More than half of all patients will eventually develop some symptoms. We're not sure of the exact cause. But chemicals in the brain ...

Novel antipsychotics, such as ziprasidone and aripiprazole, in the treatment of psychosis in PD remain controversial. Cholinesterase inhibitors are useful, especially in the presence of cognitive ...

including Parkinson's Disease Psychosis (PDP). One of the most distressing manifestations of PDP is visual hallucinations (VH), where individuals see things that are not present. Recent research ...

Age of PD onset, mean (SD) 60.5(9.9) 61.7(10.9) 61.8(12.2) 0.51 Duration (Y), mean (SD) 10.2(7.0) 7.3(5.3) 7.2(5.3) 0.002 Abbreviations: n, number; Y, years; SD, standard deviation; mH-Y, modified ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company with a market capitalization of $3.06 billion, focuses on developing and commercializing innovative medicines to address unmet ...

Bajaj Healthcare receives DCGI approval to manufacture Pimavanserin, a generic medication for treating hallucinations and delusions associated with Parkinson's disease.

Bajaj Healthcare has received an approval from the Drug Controller General of India (DCGI) to manufacture both the API and Drug Formulation of Pimavanserin, a 34 mg capsule.

Parkinson's disease psychosis (PDP) is a common and challenging complication of Parkinson's disease, characterized by hallucinations and delusions. Managing these symptoms is crucial, as they can ...